TrialThoracic cancer2019

Clinical significance of ≥ 50% PD-L1 expression with the SP263 monoclonal antibody in non-small cell lung cancer patients.

Wenbin Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.